Next-generation HIF-2α inhibitor shows promise in kidney cancer translational clinical trial
The first-in-patient, single-arm ARC-20 clinical trial, led by Dana-Farber Cancer Institute's Toni K. Choueiri, MD, has evaluated casdatifan, a next-generation HIF-2α inhibitor, as monotherapy for metastatic ...
1 Jul 15:00 · Medical Xpress